TheraRadar
← Back
Data updated: Jul 17, 2026

NOVADAQ TECH

Pharma

NOVADAQ TECH is a pharmaceutical company focused on Oncology, Immunology. Key products include SPY AGENT GREEN KIT.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

NOVADAQ TECH's Key Drugs

NOVADAQ TECH's core commercial portfolio centers on SPY AGENT GREEN KIT, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

NOVADAQ TECH's Recent FDA Approvals

New NDA/BLA approvals for NOVADAQ TECH over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NOVADAQ TECH's Therapeutic Areas

NOVADAQ TECH's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 83%
0 drugs Phase 3: 1 Phase 1: 1
Immunology 17%
0 drugs Phase 1: 1

NOVADAQ TECH's Top Competitors

NOVADAQ TECH's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NOVADAQ TECH Pipeline Snapshot

NOVADAQ TECH has 3 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 2 Phase 1.

1
Phase 3
0
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • SPY AGENT GREEN KIT leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling